Price
Frequently asked questions
What is Natera's market capitalization?
What is the Earnings Per Share (EPS) for Natera?
What are the analyst ratings and target price for Natera's stock?
What is Natera's revenue over the trailing twelve months?
What is the EBITDA for Natera?
What is the free cash flow of Natera?
What is the 5-year beta of Natera's stock?
How many employees does Natera have, and what sector and industry does it belong to?
What is the free float of Natera's shares?
Financials
Market Cap
$15.67B5Y beta
1.52EPS (TTM)
-$2.465Free Float
118.58MRevenue (TTM)
$1.36BEBITDA (TTM)
-$284.86MFree Cashflow (TTM)
-$117.81MPricing
Analyst Ratings
The price target is $123.31 and the stock is covered by 17 analysts.
Buy
16
Hold
0
Sell
1
Information
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
3,282
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker